There are 2 trials with cavatak injected into tumours combined with a checkpoint inhibiter.
On nov 14 VLA released that the combo with Keytruda had a 100% disease control rate in the first 10 patients, with 0 grade 3 or 4 adverse events.
Since the method of injecting Cavatak was the same in this trial as the Yervoy trial, AND, the 2 checkpoint inhibiters were given in their usual doses, and given they are both similar in their mechanism of action, if not exactly in the way they inhibit the "checkpoint"... one could combine these results to get a bigger picture of what is happening here.
Disease control rate for the two trials combined would be 89%, or 24/27 patients.
Grade 3 or 4 adverse events would be 1/27 or 4%.
Disease control rate is much greater than either Keytruda or Yervoy has been shown to have in trials, grade 3 or 4 adverse events are almost non-existent.
Ask yourself if you knew these results before they were announced would you have bought shares in the 80-90 cent range... of course you might go to jail for insider trading, lol, but you get my point here. You are now getting the opportunity to buy the shares at the pre-trial release price levels even though you know the results.
Remarkable.
VLA Price at posting:
85.5¢ Sentiment: None Disclosure: Held
